NCT02650271View on ClinicalTrials.gov

Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

February 2, 2021

Primary Completion Date

December 25, 2023

Study Completion Date

December 30, 2023

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Entecavir

Patients will be received entecavir (10 mg/d) before liver resection.

DRUG

Tenofovir

Patients will be received tenofovir before liver resection.

Trial Locations (1)

530021

Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University, Nanning

All Listed Sponsors
lead

Guangxi Medical University

OTHER

NCT02650271 - Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC | Biotech Hunter | Biotech Hunter